-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Inozyme Pharma, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q2 2019 to Q2 2024.
- Inozyme Pharma, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $632K, a 22.1% decline year-over-year.
- Inozyme Pharma, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $4.33M, a 31% increase year-over-year.
- Inozyme Pharma, Inc. annual Nonoperating Income (Expense) for 2023 was $4.48M, a 177% increase from 2022.
- Inozyme Pharma, Inc. annual Nonoperating Income (Expense) for 2022 was $1.61M, a 7236% increase from 2021.
- Inozyme Pharma, Inc. annual Nonoperating Income (Expense) for 2021 was $22K, a 96.4% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)